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Abstract: This review highlights the various challenges 
overcome during our recent synthetic campaign towards (–)-
leiodermatolide, a potent cytotoxic and antimitotic macrolide 
isolated from the marine sponge Leiodermatium sp. This 
structurally unprecedented macrocyclic chemotype 
represents a promising lead for anticancer drug discovery, 
provided a sustainable supply can be realised by an efficient 
chemical synthesis. Faced with the stereochemical 
ambiguities arising from our structural assignment work, a  
flexible and modular synthetic strategy was adopted for the 
construction of various key fragments, as a prelude to the 
controlled assembly of the two diene moieties. Installation of 
the nine stereocentres was achieved by the strategic use of 
boron-mediated aldol reactions of chiral ketone building 
blocks. Following the exploratory construction of the 
macrocyclic core, we revised our strategy to circumvent some 
problematic steps, enabling a highly convergent total 
synthesis of (–)-leiodermatolide. 
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1. Introduction 
Marine organisms afford a valuable reservoir of structurally 
diverse, bioactive natural products for the discovery and 
development of new cancer chemotherapeutic agents.[1] 
Several approved drugs based on novel chemotypes, 
eliciting exceptionally potent antitumour activity, have 
originated from this focused bioprospecting in the world’s 
oceans. Prominent examples are Yondelis®, Halaven® (a 
simplified version of the halichondrin family of macrolides) 
and Adcetris®, one of the first successful antibody-drug 
conjugates (ADCs), while many other marine drug 
candidates have progressed into clinical trials.[2]  
However, the potent biological activity exhibited by the 
most promising of these drug leads is often mirrored by their 
extremely scarce natural supply, such that realising a 
practical chemical synthesis and associated SAR studies are 
essential steps to opening up the bottleneck to any clinical 
development.[3] A compelling example here is the cytotoxic 
marine peptide dolastatin 10, first isolated by Pettit in low 
milligram quantities from hundreds of kilograms of the sea 
hare Dolabella auricularia,[4] which evolved into auristatin 
E as the potent microtubule-disrupting payload featured in 
Adcetris® along with many other ADCs currently in clinical 
trials.[5]  
Over the past two decades, we have enjoyed a 
rewarding association with the marine natural product 
division of the Harbor Branch Oceanographic Institute 
at Florida Atlantic University. This collaboration arose 
from our synthetic interest in discodermolide (1, Figure 
1),[6] a novel anticancer polyketide first isolated in 1990 
from the lithistid sponge Discodermia dissoluta by  
 
 
 
 
Gunasekera and co-workers.[7] Discodermolide was 
later discovered to share a similar microtubule-
stabilising mechanism of action to taxol, with a common 
binding site on β-tubulin, whilst exhibiting potent 
antiproliferative activity against drug-resistant cancer 
cell lines and inhibiting the growth of solid tumours in 
animal models. Following an impressive resupply 
campaign, a large-scale synthesis of discodermolide was 
achieved by Novartis process chemists, relying on the 
prior art of the Smith group[8] and ourselves,[6] enabling 
this promising cancer chemotherapeutic agent to enter 
clinical trials.[9]  
In 2003, toxicity issues led to discodermolide being 
dropped from further clinical development. Whilst 
around that time, the Harbor Branch team of Wright 
isolated a macrocyclic polyketide from a deep-water 
lithistid sponge of the family Corallistidae, and 
discovered that it was also a promising microtubule-
stabilising agent and generally demonstrated superior 
antiproliferative activity.[10] This transpired to be 
dictyostatin, a 22-membered macrolide previously 
reported by the Pettit group[11] and, although structurally 
related to discodermolide, the 3D stereostructure was  
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Figure 1. Structures of the marine-sponge derived antimitotic 
agents discodermolide (1) and dictyostatin (2), and the 
designed synthetic hybrid 3.  
 
not fully assigned. Using a combination of detailed 
NMR analysis and molecular modelling, we were able 
to determine the complete stereochemistry of 
dictyostatin as shown in 2. Soon after reporting this 
structural assignment,[12] it was validated by the 
independent total syntheses from ourselves[13] and that 
of the Curran group.[14] The resulting sustainable supply 
afforded by chemical synthesis then opened up 
extensive biological studies on dictyostatin, along with 
the design and synthesis of various analogs including 
the highly potent hybrid 3 with discodermolide. [15]   
 
Following these productive collaborations, we next 
joined forces with Amy Wright and her colleagues to 
determine the full 3D structure of leiodermatolide,[16,17] 
another promising anticancer polyketide of lithistid sponge 
origin. As the main focus of this review, we give an account 
of our structural assignment work and subsequent efforts to 
develop an efficient synthesis of this intriguing bioactive 
macrolide to enable the in vivo evaluation of its antitumour 
efficacy and SAR studies. 
 
1.1. Isolation of Leiodermatolide 
Using a manned submersible, sample collections of the 
lithistid sponge Leiodermatium sp. were made off the coast 
of Ft. Lauderdale, Florida, and in Wemyss Bight in the 
Bahamas. Bioassay-guided fractionation of the resulting 
sponge extracts and extensive chromatographic purification 
led to the isolation of (–)-leiodermatolide as a colorless 
powder (0.0011% wet weight), corresponding to a unique 
polyketide chemotype with the assigned planar structure 4 
(Figure 2).[16]  
1.1.1. Biological Activity of Leiodermatolide 
In their initial patent application,[16] the Harbor Branch 
group disclosed that leiodermatolide exhibited highly potent 
antiproliferative activity (IC50 <10 nM) against a panel of 
human cancer cell lines, whilst showing reduced toxicity to 
normal cells. It was also shown to retain activity in drug-
resistant cell lines, including those overexpressing the P-
glycoprotein efflux pump. Cell-cycle arrest occurred at the 
G2/M phase, accompanied by abnormal mitotic spindle 
formation, a characteristic response to anticancer agents that 
interact with tubulin (e.g. taxol, discodermolide, 
dictyostatin).[17] The mechanism of action was independently 
investigated at Pfizer, working with synthetic material made 
available from the Fürstner group.[18] These studies revealed 
several unusual, concentration-dependant effects, not 
previously observed for microtubule-targeting agents. 
Interestingly, both the Harbor Branch and Pfizer findings 
indicated that leiodermatolide neither inhibited nor induced 
the assembly of purified tubulin in vitro, and no evidence for 
an interaction with tubulin was found. This suggests that it 
affects microtubule dynamics without directly interacting 
with tubulin, indicating a novel mechanism of action distinct 
from that of other known anticancer drugs. It was also 
suggested that leiodermatolide could be acting as a 
centrosome-declustering agent but this hypothesis requires 
verification. Preliminary evaluation in vivo in a mouse 
model of metastatic pancreatic cancer led to a significant 
reduction in tumour size, underscoring leiodermatolide’s 
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clinical potential as a new experimental chemotherapeutic 
lead for pancreatic and other solid tumours.[19] 
1.1.2. Structural Elucidation of Leiodermatolide 
At the outset, extensive NMR spectroscopic analysis 
performed by the Wright group enabled the determination of 
the planar structure 4 for (–)-leiodermatolide. The 16-
membered macrocyclic core contains six stereocentres and 
is appended with a side chain terminating in a δ-lactone ring 
bearing three further stereocentres. Notable structural 
features included the presence of two conjugated dienes, one 
(E,E)-  and one (Z,Z)-configured, and a pendant carbamate 
moiety at C9. 
 
Figure 2. Evolving structural understanding of leiodermatolide. 
Following a tentative stereochemical assignment, a 
precious sample of leiodermatolide was provided for 
further detailed NMR analysis at Cambridge.[17] 
Extensive nOe and coupling constant analysis using 
Murata’s method first allowed us to determine the 
relative configuration of the three isolated stereoclusters 
at C6–C9, C14–C15 and C21–C25 (Figure 2). 
As the distal nature of the two stereoclusters within 
the macrocyclic core prevented the confident 
determination of their relative configuration by NMR 
analysis alone, chemical derivatisation and molecular 
modelling were employed. The C7,C21-bis-MTPA 
esters of leiodermatolide were initially prepared in an 
attempt to determine the absolute configuration by the 
advanced Mosher’s method, however, irregular ΔδSR 
values meant this approach proved unfruitful. Seeking 
increased confidence for the assignment of the 
stereochemistry within the macrocyclic core, we turned 
to using the computational DP4 GIAO-NMR probability 
method.[20] The resulting combined 1H and 13C chemical 
shift correlations on appropriate virtual fragments 
predicted a single diastereomer with >99% probability 
for the separate macrolactone (C1–C15) and δ-lactone 
(C21–C25) rings. Attempts to relate the configuration 
between these two distinct regions, however, proved 
inconclusive. Nevertheless, this combined experimental 
and computational NMR analysis succeeded in reducing 
the number of stereoisomers to a more manageable four. 
In 2011, we reported the 3D representation 5 for (–)-
leiodermatolide as one of these permutations, which 
fortuitously turned out to be the correct structural 
assignment. 
At around this time, we embarked on our synthetic 
campaign to potentially access any of the four candidate 
structures, in conjunction with performing detailed 
NMR and chiroptical correlations, as a means of 
unequivocally determining both the relative and 
absolute configuration of leiodermatolide. 
 
1.1.3. Synthetic Efforts Towards Leiodermatolide 
Although lacking detailed knowledge of the stereochemical 
assignment for leiodermatolide, the Maier group launched 
their synthetic efforts towards a tentative structure. They 
first reported a synthesis of several fragments, including a 
diastereomeric macrocyclic core, epimeric at the two 
methyl-bearing stereocentres at C8 and C10 relative to those 
assigned in structure 5.[21] In 2016, they subsequently 
reported the construction of a macrocyclic core with the 
required revision to the stereochemistry.[22] 
In 2012, the Fürstner group disclosed a completed 
synthesis of both candidate diastereomers corresponding 
to our published structure 5 of (–)-leiodermatolide.[23] 
Careful 1H NMR comparison showed that the compound 
with the diastereomeric side chain was distinguishable 
by minor differences in peak shape, while the NMR data 
for 5 exactly matched that obtained for leiodermatolide. 
Correlation of the optical rotation also confirmed that 
structure 5 represents the natural enantiomer. 
Subsequently, the Fürstner group reported an improved 
synthesis of (–)-leiodermatolide along with further 
biological results.[18]  
In 2011, we reported the stereocontrolled synthesis 
of the macrocyclic core, verifying that our proposed 
structure and relative configuration for this C1–C17 
region were correct.[24] Completion of the synthesis of 5 
from this point, however, required modification to our 
initial strategy. The remainder of this review details 
these efforts, leading to our successful total synthesis of 
(–)-leiodermatolide.[25] 
2. Investigations Culminating in the 
Cambridge Total Synthesis of (–)-
Leiodermatolide 
2.1 Initial Synthetic Strategy Adopted Towards 
Leiodermatolide  
At the outset, the key consideration when designing our 
initial synthetic approach to leiodermatolide was the 
requirement to be able to access both candidate 
diastereomers. As outlined in Scheme 1, we arbitrarily 
targeted the synthesis of ent-5 (the mirror image of our 
published structure 5) and its diastereomer, where 
disconnection across the C17–C18 bond served to separate 
the side chain from the macrocyclic core 6. We anticipated 
that the construction of each enantiomer 7 and ent-7 of the 
C18–C25 fragment containing the δ-lactone ring should be 
reasonably straightforward (see section 2.1.3). An  
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Scheme 1. Synthesis plan for leiodermatolide (ent-5) based on 
proposed site-specific fragment coupling using the linchpin 8. 
adventurous, site-specific, fragment coupling strategy for 
the stepwise construction of the two conjugated diene 
moieties was proposed based on the use of the linchpin 
fragment 8. In detail, it was planned that a Stille cross-
coupling between the C1–C11 stannane 9 and the more 
reactive vinyl iodide at C12 in 8 would initially forge the 
(Z,Z)-diene, followed, after macrolactonisation, by a Suzuki 
coupling of the remaining bromide at C17 with the side 
chain fragment 7 (or ent-7) to install the (E,E)-diene.  
2.1.1. Synthetic Studies Directed Towards the 
Macrocyclic Core Provide Support for the Assigned 
Stereochemistry 
Following this flexible plan, our synthesis of the 
macrocyclic core 6 commenced as shown in Scheme 2, with 
controlled installation of the requisite six stereocentres and 
four alkenes. A key feature of this route is the efficient 
introduction of the syn-related C8 and C9 stereocentres 
using chiral ligand-mediated boron aldol methodology 
developed in our group.[26] To provide a masked (Z)-vinyl 
stannane for the projected Stille cross-coupling step, 3,3-
dibromoacrolein 10 served as the aldehyde partner. Using 
the (Z)-selective enolisation of the ethyl ketone 11 (derived 
from (S)-Roche ester) with ((–)-Ipc)2BOTf/iPr2NEt, this 
pivotal aldol addition proceeded with excellent stereocontrol 
(>20:1 dr) to afford the syn-adduct 12. An Evans-
Tishchenko reduction[27] of this β-hydroxy ketone then 
secured the desired 1,3-anti-diol, again with excellent 
stereocontrol (>20:1 dr). Protection as the bis-TBS ether 13 
required the rather forcing conditions of TBSOTf at 0 °C to 
effect the second silylation at C7, which indicated the 
feasibility of differentiating the C7 and C9 hydroxyl groups. 
This observation would later have a critical impact on our 
strategy for the site-selective installation of the carbamate 
moiety in the endgame.  
 
Scheme 2. First-generation synthesis of the C1–C11 fragment 
9 of leiodermatolide. DDQ = 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone, DMP = Dess–Martin periodinane, Ipc = 
isopinocampheyl, Py = pyridine, TBS = tert-butyldimethylsilyl 
Straightforward manipulation progressed 13 to the 
tertiary allylic alcohol 14, in preparation for the installation 
of the trisubstituted double bond and C1 ester. Whilst the 
initially explored Claisen rearrangement methodology 
proceeded with disappointing selectivity, a viable alternative 
was found in the Lewis acid-mediated rearrangement of 
allylic alcohols developed by Fuchter.[28] Thus treating the 
magnesium alkoxide derived from 14 with TiBr4 effected 
the desired rearrangement, and the resulting allylic bromide 
15 was displaced with the anion of dimethylmalonate. 
Following decarboxylation to give 16, our attention turned 
to converting the C11 terminus into the (Z)-vinyl stannane. 
While the controlled semi-reduction of the dibromide to the 
(Z)-vinyl bromide proceeded smoothly under palladium-
catalysed conditions (Bu3SnH, Pd(PPh3)4), subsequent 
attempts at conversion into the stannane proved unrewarding. 
After extensive experimentation, a degree of success was 
achieved by first cleaving the sterically demanding TBS 
ethers, followed by stannylation under Wulff-Stille 
conditions ((SnMe3)2, Pd(PPh3)Cl2, Li2CO3)[29] to provide 9 
in a disappointing but workable yield. Going forward, this 
problematic transformation was clearly a bottleneck needing 
to be addressed in evolving our strategy. 
The highly stereocontrolled construction of the C12–
C17 bis-vinyl halide fragment 8 also relied on versatile 
boron aldol methodology developed in our group 
(Scheme 3).[30] This commenced with the anti-selective 
aldol addition between lactate-derived ethyl ketone 18 
and aldehyde 19 which efficiently configured the C14 
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and C15 stereocentres in the resulting adduct 20 (>20:1 
dr). Following silylation of the alcohol and ketone 
reduction, oxidative glycol cleavage enabled a Stork-
Zhao olefination[31] of the resulting aldehyde to form the 
desired (Z)-vinyl iodide 8, in readiness for constructing 
the macrocyclic core. 
In practice, the adventurous Stille coupling of the 
two fragments 8 and 9 proceeded in the planned site-
specific manner, under the palladium(0)/copper(I) 
conditions developed by Fürstner (Pd(PPh)3)4, CuTC, 
[Bu4N+][Ph2PO2-]),[32] to  cleanly afford the desired 
(Z,Z)-diene 21. Saponification of the ester and acid-
mediated desilylation then set the stage for exploring 
the critical macrolactonisation step on the triol acid 22. 
Gratifyingly, this proceeded in excellent yield under 
Yamaguchi conditions[33] with complete regioselectivity 
for the desired 16-membered ring in 23. At this stage, 
our synthetic efforts toward leiodermatolide were 
making excellent headway, and we did not anticipate the 
problems waiting ahead! 
2.1.2. Problematic Introduction of the C9-Carbamate and 
Support for the Assigned Stereochemistry 
On the basis of the observation that the C9 hydroxyl group 
in intermediate 13 could be selectively silylated (see section 
2.1.1), it was envisaged that the attachment of the carbamate 
could be achieved at the required C9 position on the 
macrocycle 23. Disappointingly, treatment of 23 with 
trichloroacetyl isocyanate followed by hydrolytic work-
up[34] provided only a 3:2 mixture of regioisomers, 
favouring the undesired C7 carbamate 24. Following 
chromatographic separation of these isomers, detailed 1H 
and 13C NMR comparison of the C9 carbamate 6 with 
leiodermatolide revealed an excellent correlation, lending 
strong support to our proposed structural assignment for the 
macrocyclic core. While the NMR correlation supported the 
assigned relative stereochemistry, the (+)-sign of the 
specific rotation for truncated macrocycle 6 turned out to be 
opposite to natural (–)-leiodermatolide. Although the 
structures are different, this result was cautiously taken to  
suggest that we had possibly started our synthetic efforts in 
the incorrect enantiomeric series.  
2.1.3. Synthesis and Planned Attachment of the Side 
Chain Fragment 
In order to gain further evidence for our proposed 
stereochemical assignment in the δ-lactone ring of the side 
chain, both epimers of the C21 tertiary alcohol were targeted 
as shown in Scheme 4. Firstly, the C22 and C23 
stereocentres were efficiently installed using a boron-
mediated aldol reaction of the lactate-derived ketone (S)-18 
with propionaldehyde to afford 25, which following an allyl 
Grignard addition was elaborated into the ketone 26. The 
two C21 epimers, 27 and 28 respectively, could then be 
selectively accessed either from 26a via an intramolecular 
Reformatsky reaction or from 26b via an intermolecular 
Mukaiyama aldol reaction[35] respectively. Detailed NMR 
comparison of these δ-lactones with the corresponding 
natural product data showed a good match for 28, in support 
of our proposed assignment in structure 5.  
 In preparation for the planned side chain attachment to 
the macrolide core 6 via a Suzuki coupling, the alkene of 28 
was elaborated by a Takai-type olefination of the derived 
aldehyde into the vinyl boronate 7. Disappointingly, the 
final Suzuki fragment coupling to afford leiodermatolide 
could not be realised, due to the vinyl bromide in 6 proving 
stubbornly unreactive under the various palladium-catalysed 
conditions explored.  
2.2. Evolution of the Synthesis Plan 
At this juncture, a revision of our synthetic strategy in 
Scheme 2 was clearly necessary to overcome the problems 
encountered in the associated exploratory studies. We first 
decided to resume work in the enantiomeric series, i.e. now 
targeting our originally proposed structure 5 in Scheme 5. 
An essential perturbation was the replacement of the C17 
vinyl bromide with a more reactive iodide to help facilitate 
the attachment of the full side chain. As preliminary studies  
 
 
 
 
Scheme 3. Synthesis of the C12–C17 fragment 8 and its site-specific Stille coupling with 9, and progression to the macrocyclic core 6. CSA = 
camphor sulfonic acid, CuTC = copper thiophene-2-carboxylate, DMAP = 4(dimethylamino)pyridine, TCBC = 2,4,6-trichlorobenzoyl chloride
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Scheme 4. Synthesis of the side chain fragment 7. TMS = 
trimethylsilyl 
of the Stille cross-coupling reaction on the bis-vinyl iodide 
analogue of fragment 8 resulted in little or no 
regioselectivity, a bis-halide linchpin was no longer 
considered a viable option. Our fragment coupling strategy 
was thus revised to employ a suitable C13–C17 fragment 29 
to assemble the full side chain containing the δ-lactone, 
prior to installation of the C12 vinyl iodide in 30 and its 
Stille coupling with the C1–C11 fragment 31. This would 
make our proposed route more convergent overall while 
lengthening the reaction sequence that might need to be 
repeated in order to attach both diastereomeric side chains. 
Despite the initially unpromising results, it was decided to 
persist with installing the C9 carbamate at a late stage on the 
undifferentiated 1,3-diol 32. It was felt that this 
regioselectivity problem could be overcome and that the 
endgame would be simplified by the avoidance of additional 
protecting group manipulations. The two issues with the 
synthesis of the original C1–C11 fragment 9 were the low 
yielding installation of the vinyl stannane and the number of 
steps required to introduce the trisubstituted alkene. An 
entirely new strategy to construct the revised C1–C11 
fragment 31 was thus pursued in an attempt to improve 
these matters.  
2.2.1 A Revised Approach to the C1–C11 Fragment 
The resulting second-generation synthesis of the western 
fragment starts out with the Roche ester-derived Weinreb 
amide 33 (Scheme 6), which was elaborated by a Grignard 
addition into the ketone 34. The trisubstituted double bond 
was constructed via controlled enolisation of ketone 34 with 
LiHMDS before trapping with Comins’ reagent[36] to form 
the (E)-vinyl triflate 35. After extensive optimisation, the 
best conditions for installation of the methyl group were 
found to be Suzuki coupling of 35 using trimethyl 
boroxine.[37] Manipulation of 36 to the aldehyde 37 then set  
 
 
Scheme 5. Revised synthesis plan for leiodermatolide (5).  
  
the stage for a boron-mediated anti-aldol addition with the 
lactate-derived ethyl ketone (R)-18. Notably, this marked the 
third application of this versatile chiral ketone in our 
leiodermatolide synthesis, affording adduct 38 with 
excellent control over the installation of the C7 and C8 
stereocentres (96%, >20:1 dr). To introduce the remaining 
C9 stereocentre, the β-hydroxy ketone 38 was next 
elaborated into the ynone 39. Both the Evans-Tischenko[27] 
and Evans-Saksena[38] protocols for 1,3-anti reduction were 
ineffective with this substrate. The former yielded the 
products of a retro-aldol–aldol–Tischenko pathway,[39] while 
the latter conditions led to poor stereocontrol. It was 
proposed that this was due to the small size of the alkyne 
substituent, reducing its preference to occupy an equatorial 
position in the transition state. The logical way forward was 
to first effect the conversion of the alkyne to the larger (Z)-
vinyl iodide to improve the stereocontrol in the reduction 
step. Kishi’s procedure for conjugate addition of an iodide 
nucleophile to an ynone under acidic conditions proved 
rewarding, preferentially leading to the desired (Z)-vinyl 
iodide 40.[40] Gratifyingly, the Evans-Saksena reduction now 
afforded exclusively the desired 1,3-anti diol 41. Conversion 
to the vinyl stannane was then achieved by lithiation and 
trapping with tributyltin chloride, with or without acetonide 
protection of the diol moiety. This afforded the desired C1–
C11 fragments 31 and 42 in a significantly improved yield 
over the first-generation approach (20% yield over 14 steps 
for 42 vs 6% yield over 14 steps for 9).  
2.2.2 Second-Generation Fragment Coupling Sequence 
The existing routes to the C12–C17 and C18–C25 fragments 
previously used to access the macrocyclic core 6 were 
adapted based on experience, as shown in Scheme 7. The 
vinyl bromide in aldehyde 19 was replaced with a more 
reactive iodide, as discussed in section 2.2. During model 
studies into formation of the C17–C18 bond, the TES ether 
at C15 had been observed to be partially labile under the 
basic conditions required for Suzuki coupling and so this  
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d) BrCH2C(O)Br
e) SmI2
46%, dr >20:1
O
TMSO
O
BO
O
A
7
21
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25
18
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23 Stille coupling
Macrolactonisation
HO
HO
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I
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SnMe3
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O
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O
TMSO
I
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(Pin)B
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1
11
12
1
17
18
17
18
25
Strategy Evolution in the Total Synthesis of (–)-Leiodermatolide 
 7 
 
 
 
Scheme 6. Improved synthesis of the C1–C11 fragment 42. Comins reagent = 2-(Tf2N)-5-Cl(C3H3N), LiHMDS = lithium hexamethyldisilylazide 
 
was replaced with a more robust TBS group in 29. 
While the anticipated Suzuki coupling between 29 and 
ent-7 proceeded smoothly under thallium-mediated 
conditions, it was proposed that several functional group 
manipulations could be avoided by employing a Heck 
reaction instead. This was explored with 29 and 43, and 
an efficient Heck coupling procedure[41] using Pd(OAc)2 
and Ag2CO3 was successfully developed that cleanly 
afforded the (E,E)-diene 44. The terminal diol in 44 was 
then elaborated into the (Z)-vinyl iodide 30 again using 
a Stork-Zhao olefination,[31] in readiness for the key 
Stille cross-coupling with the (Z)-vinyl stannane 31 or 
42. As shown in Scheme 8, this pivotal step proceeded 
smoothly to unite the two halves of the carbon backbone 
to generate the requisite (Z,Z)-dienes 45 and 46. The 
originally devised endgame called for the C7 and C9 
alcohols to remain unprotected and thus required a 
challenging selective oxidation in order to obtain the 
correct oxidation level at C1 for macrolactonisation. In 
practice, this proved unsuccessful and necessitated a 
minor revision of the strategy, employing the acetonide 
46 instead. The oxidations at C1 were successfully 
effected and removal of the C15 TBS ether revealed the 
leiodermatolide seco-acid 47. Macrocyclisation 
proceeded smoothly under Yamaguchi conditions to 
engage the C15 alcohol and the acetonide was then 
cleaved to reveal 32, as the putative precursor to 
leiodermatolide 
2.2.3 Completion of the Cambridge Total Synthesis of (–
)-Leiodermatolide: Attachment of the C9 Carbamate 
A key aspect of our strategy was the absence of differential 
protection of the C7 and C9 hydroxyl groups. Completion of 
the leiodermatolide synthesis thus hinged on achieving the 
site-selective formation of the requisite carbamate at C9. 
From molecular modelling, the allylic nature of the C9 
position in 32 compared to the doubly α-branched C7 
position suggested it was less sterically hindered and 
potentially more reactive to derivatisation. As with the 
previously prepared truncate 23 discussed in section 2.1.2, 
however, treatment with trichloroacetyl isocyanate 
disappointingly led to a mixture of regioisomers, again 
favouring the undesired carbamate. Much effort went into 
attempting to overturn this undesired selectivity but without 
success. Frustratingly, it was noted that conventional 
esterification and silylation reactions, along with formation 
of the dimethylcarbamate using the carbamoyl chloride, all 
proceeded with pronounced selectivity for the desired C9 
position. 
 
  
Scheme 7. Synthesis of revised C13–C17 fragment 29 and 
Heck coupling with 43 to construct the (E,E)-diene in 30. 
This indication that the C9 alcohol was indeed the more 
reactive position in the substrate 32 and that the 
O OTBS
O H
OTBS
HO
OBz
O
OTBS
HO
O
OTBS
HO
O
I
OTBS
HO
HO
I
OTBS
87%
[e) Me2C(OMe)2, 
    PPTS]
f) t-BuLi, 
    Bu3SnClRO
RO
SnBu3
OTBS
N
PMBO OMe
O
Me
6 TBSO(CH2)4MgBr
R OTBS
LiHMDS, 
Comins reagent
35:  R = OTf
36:  R = Me
(MeBO)3, Pd(PPh3)4
70%, 2 steps
93%
83%
OBz
O
Cy2BCl, Et3N
(R)-18 96%, dr > 20:1
33 34 37
38
69%
39
NaI, AcOH
81%
40
Me4NBH(OAc)3
97%, dr > 20:1
4131:  R = H 64%
42:  R = CMe2 81%
PMBO PMBO
7
8
9
11
1
a) DDQ
b) DMP
c) TMSCl
b) LiCCTMS
c) K2CO3
d) NaIO4
O
O
TMSO
OTBS
I
a) NaIO4 
b) [PPh3CH2I]I, 
    NaHMDS
62%, 2 steps
O
O
TMSO
O
O
TMSO
OTESOH
HO
Pd(OAc)2, 
Ag2CO3
73%
O
BzO
OH
I
OHC
I
I
OTBSOH
HO
91%
(S)-18
Cy2BCl, Et3N
90%, dr > 20:1 3 steps
43
44
30
29
ent-28
TMSCl
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 8 
isocyanate reagent was behaving anomalously pointed 
us towards a solution to the problem. Silylation of both 
alcohols in 32 could be achieved using trimethylsilyl 
imidazole and the C9 silyl ether was then selectively 
cleaved under mildly acidic conditions (PPTS, MeOH). 
Gratifyingly, carbamate formation on treatment with 
with trichloroacetyl isocyanate and acidic removal of 
the remaining TMS ether at C7 then afforded only (–)-
leiodermatolide (5). To our satisfaction, all NMR and 
chiroptical data for this synthetic material correlated 
with those already recorded for the natural sample of (–
)-leiodermatolide provided by Amy Wright. 
 
 
 
 
Scheme 8. Stille coupling of fragments 30 and 42, followed by 
macrolactonisation and elaboration into (–)-leiodermatolide (5). 
BAIB = bis(acetoxy)iodobenzene, PPTS = pyridinium para-
toluenesulfonate, TBAF = tetrabutylammonium fluoride, 
TEMPO = 2,2,6,6-tetramethylpiperidine 1-oxyl 
3. Summary 
Our successful total synthesis of (–)-leiodermatolide[25] 
provided further verification of the assigned 3D structure 5. 
While our initial studies towards the construction of the 
leiodermatolide macrocycle and side chain provided strong 
support for the relative configuration proposed in 5, this 
plan proved to be unsuitable for achieving the total synthesis 
itself. Evolution of our strategy with judicious revisions to 
the fragment couplings and a redesigned synthesis of the 
C1–C11 fragment addressed these problems, and led to the 
highly convergent assembly of the leiodermatolide 
backbone. While the regioselective carbamate installation in 
the endgame initially proved problematic, it was ultimately 
solved leading to completion of the total synthesis of (–)-
leiodermatolide in 23 steps LLS and 3.2% overall yield. 
Notably, every element of sp3 and sp2 stereochemistry is 
efficiently controlled with >20:1 selectivity, with a minor 
exception being the installation of  the Δ10,11 alkene (10:1 
Z/E). 
In conclusion, the marine macrolide leiodermatolide 
stands out as an excellent example of how a 
combination of experimental and computational NMR 
analysis, together with chemical synthesis, can be used 
to achieve the complete structural assignment of 
biologically important natural products. Inevitably, 
NMR analysis takes the minority of the time and reveals 
the majority of the structural information but relies on 
synthetic efforts to fill in the gaps. Going forward, the 
development of a practical total synthesis of 
leiodermatolide should enable access to both a 
sustainable supply and designed analogs for further 
evaluation of this promising new experimental 
antimitotic drug in cancer chemotherapy.[19,42] 
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